Josh Henderson, DO
Internal Medicine · Mobridge, SDNPI 1730334384
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 295 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 295 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$767
- Lilly USA, LLC$520
- Novo Nordisk$485
- Astellas Pharma US Inc$472
- Johnson & Johnson$360
- Boehringer Ingelheim$322
- plus $2K from 16 others
What the payments were for
- Food & beverage$4,54198%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 48 | $767 |
| Lilly USA, LLC | 32 | $520 |
| Novo Nordisk | 31 | $485 |
| Astellas Pharma US Inc | 21 | $472 |
| Johnson & Johnson | 29 | $360 |
| Boehringer Ingelheim | 21 | $322 |
| AstraZeneca | 19 | $318 |
| AbbVie(2 entities) | 14 | $246 |
| Novartis | 12 | $209 |
| Merck | 21 | $208 |
| Pfizer | 11 | $146 |
| Sanofi-aventis U.S. LLC | 7 | $113 |
| Exact Sciences | 6 | $95 |
| E.r. Squibb & Sons, L.L.C. | 6 | $90 |
| Bayer | 6 | $87 |
| Phathom Pharmaceuticals, Inc. | 4 | $55 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Smith+Nephew | 1 | $34 |
| Integra Lifesciences Corporation | 1 | $24 |
| Vertex | 1 | $23 |
| Medtronic | 1 | $15 |
| Checkpoint Surgical, Inc | 1 | $12 |
How this compares
$4,641 in reported general payments places this provider in the 90th percentile of 178 internal medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 204 | $134,078 |
| OzempicSemaglutide | 117 | $118,562 |
| JardianceEmpagliflozin | 75 | $64,950 |
| XolairOmalizumab | 18 | $44,574 |
| MounjaroTirzepatide | 32 | $32,201 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $29,573 |
| FarxigaDapagliflozin Propanediol | 21 | $29,563 |
| MyrbetriqMirabegron | 36 | $18,251 |
| RybelsusSemaglutide | 21 | $18,157 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $14,875 |
| Spiriva RespimatTiotropium Bromide | 29 | $14,398 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $14,380 |
| LinzessLinaclotide | 25 | $14,103 |
| KerendiaFinerenone | 19 | $11,155 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $8,992 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $485 | $136,719138 claims |
| PfizerEliquis | $146 | $134,078204 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $322 | $79,348104 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $318 | $44,43846 claims |
| Lilly USA, LLCMounjaro | $520 | $32,20132 claims |
| Astellas Pharma US IncMyrbetriq | $472 | $18,25136 claims |
| AbbVieLinzess | $246 | $14,10325 claims |
| MerckJanuvia, Janumet | $208 | $12,12623 claims |
| BayerKerendia | $87 | $11,15519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 178 internal medicine providers in South Dakota.
Other internal medicine in Mobridge
- Travis HendersonMobridge$6K
- Jennifer MayRapid City$52K
- Richard BeasleyRapid City$25K
- Issam TurkRapid City$14K
- Janell PowellSioux Falls$7K
- Maaz BadshahSioux Falls$6K
- Robert AllisonPierre$6K
- Darrell PlumagePierre$6K
- Wendy VetterSioux Falls$5K
- Hollis NipeWatertown$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.